
|Articles|March 1, 2002
Infliximab dramatically clears severe psoriasis
New Orleans - The experience of a teenage girl treated successfully with infliximab (Remicade) for severe, recalcitrant psoriasis of her hands and feet indicates the value of the TNF-alpha chimeric monoclonal antibody as a therapeutic option for psoriasis.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Eli Lilly Trial Shows Superior Outcomes With Ixekizumab and Tirzepatide in Patients With PsA and Obesity
2
Phase 2a Evaluation of Dual OX40L/TNFα Antibody Begins in HS
3
FDA Feedback Supports BLA Pathway for Sonelokimab in HS
4
Interim Analysis Leads to Early Termination of DUPLEX-AD Study
5


















